TY - JOUR
T1 - Review of methods for detecting glycemic disorders
AU - Bergman, Michael
AU - Abdul-Ghani, Muhammad
AU - DeFronzo, Ralph A.
AU - Manco, Melania
AU - Sesti, Giorgio
AU - Fiorentino, Teresa Vanessa
AU - Ceriello, Antonio
AU - Rhee, Mary
AU - Phillips, Lawrence S.
AU - Chung, Stephanie
AU - Cravalho, Celeste
AU - Jagannathan, Ram
AU - Monnier, Louis
AU - Colette, Claude
AU - Owens, David
AU - Bianchi, Cristina
AU - del Prato, Stefano
AU - Monteiro, Mariana P.
AU - Neves, João Sérgio
AU - Medina, Jose Luiz
AU - Macedo, Maria Paula
AU - Ribeiro, Rogério Tavares
AU - Filipe Raposo, João
AU - Dorcely, Brenda
AU - Ibrahim, Nouran
AU - Buysschaert, Martin
PY - 2020/7
Y1 - 2020/7
N2 - Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.
AB - Prediabetes (intermediate hyperglycemia) consists of two abnormalities, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by a standardized 75-gram oral glucose tolerance test (OGTT). Individuals with isolated IGT or combined IFG and IGT have increased risk for developing type 2 diabetes (T2D) and cardiovascular disease (CVD). Diagnosing prediabetes early and accurately is critical in order to refer high-risk individuals for intensive lifestyle modification. However, there is currently no international consensus for diagnosing prediabetes with HbA1c or glucose measurements based upon American Diabetes Association (ADA) and the World Health Organization (WHO) criteria that identify different populations at risk for progressing to diabetes. Various caveats affecting the accuracy of interpreting the HbA1c including genetics complicate this further. This review describes established methods for detecting glucose disorders based upon glucose and HbA1c parameters as well as novel approaches including the 1-hour plasma glucose (1-h PG), glucose challenge test (GCT), shape of the glucose curve, genetics, continuous glucose monitoring (CGM), measures of insulin secretion and sensitivity, metabolomics, and ancillary tools such as fructosamine, glycated albumin (GA), 1,5- anhydroglucitol (1,5-AG). Of the approaches considered, the 1-h PG has considerable potential as a biomarker for detecting glucose disorders if confirmed by additional data including health economic analysis. Whether the 1-h OGTT is superior to genetics and omics in providing greater precision for individualized treatment requires further investigation. These methods will need to demonstrate substantially superiority to simpler tools for detecting glucose disorders to justify their cost and complexity.
KW - Biomarkers
KW - Cardiovascular disease
KW - Continuous glucose monitoring
KW - Glycemic variability
KW - HbA1c
KW - Metabolomics
KW - Oral glucose tolerance test
KW - Prediabetes
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85086447364&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2020.108233
DO - 10.1016/j.diabres.2020.108233
M3 - Review article
C2 - 32497744
AN - SCOPUS:85086447364
SN - 0168-8227
VL - 165
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 108233
ER -